Cleerly, Inc.

Vensana previously collected $325 million in late 2021, which followed up on a $225 million haul in 2019. Since then, the firm has supported more than 20 medtech developers—and said it has logged at least six exits that add up to nearly $3 billion. \n The venture firm Vensana Capital has raised its third medtech-focused fund in the past six years, with $425 million in new commitments to support growing medical device and data science startups.According to the outfit, the oversubscribed fund was backed by Vensana’s current limited partners as well as new, unnamed institutional investors, and brings its total capital under management to about $1 billion since starting out in 2019.“We are incredibly proud of the progress Vensana has made since launch as we work tirelessly to build the leading medtech investment and company building platform, and we are beyond grateful for the continued strong support of our limited partners,” Managing Partner Kirk Nielsen said in a statement. Vensana previously collected $325 million in late 2021, which followed up on a $225 million haul in 2019. Since then, the firm has supported more than 20 medtech developers—and said it has logged at least six exits that add up to nearly $3 billion.That includes the 2021 IPO of the neurostim company CVRx, as well as the acquisitions of Relievant Medsystems by Boston Scientific; Artelon by Stryker; Personal Genome Diagnostics by Labcorp; and Intact Vascular and Vesper Medical, both by Philips.Other companies include the heart disease-focused FIRE1 and Cleerly, which recently posted $120 million and $106 million funding rounds for their own respective efforts.“Our entire team is excited about the opportunity ahead as we continue to partner with entrepreneurs who are transforming healthcare with breakthrough innovations in medical technology,” said Managing Partner Justin Klein. “We approach each day mindful of the impact that our work has on the missions of our limited partners, on our portfolio companies and their teams, and—most importantly—on our clinician partners and their patients.”

SAN FRANCISCO--( BUSINESS WIRE )--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced significant milestones in its mission to transform healthcare delivery. In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai expanded its reach to serve 1,700 hospitals with a broad user base that grew by more than 30% to reach 60,000 healthcare providers in the United States. This rapidly growing footprint, driven by new product innovation and real-world evidence, demonstrates the company’s commitment to increase access to life-saving treatments. “This year has surpassed our expectations as Viz.ai’s footprint in healthcare continued to grow with the majority of the 50 largest healthcare systems in the U.S. adopting our platform,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “This reaffirms Viz.ai’s position as the leading, trusted AI-powered platform and our dedication to delivering tools that empower providers, streamline workflows and improve patient outcomes. As we continue to broaden our patient impact with leading life science collaborators and healthcare systems, we look to accelerate better patient care by leveraging AI-driven insights and care coordination in 2025.” In 2024, Viz.ai introduced new products and capabilities to its Viz.ai One™ enterprise platform, which now includes more than 48 clinical AI modules. Key innovations include the introduction of the Viz ICH Plus™ algorithm for automated volumetric assessment and cutting-edge 3D CT angiography functionality, as well as the launch of Viz Connect® for cryptogenic stroke and Viz ACS for acute coronary syndrome. These enhancements further strengthen Viz.ai’s offering in cardiovascular and neurovascular care pathways, enhancing functionality in both acute and non-acute treatment scenarios and underscoring the company’s commitment to transform healthcare through AI-driven solutions. With 24 new clinical studies this year and more than 100 clinical publications and abstracts to date, Viz.ai has continued to demonstrate substantial real-world evidence of the positive impact of its AI-powered care coordination on patient outcomes and economic efficiency. Three studies at the American College of Cardiology Scientific Session 2024 demonstrated the positive impact of Viz.ai’s hypertrophic cardiomyopathy module on suspected disease detection and patient triage for improved care. Another recent study on pulmonary embolism (PE) showed that the Viz PE solution significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk. Additionally, six studies presented at the International Stroke Conference (ISC) 2024 showed the real-world impact of Viz.ai on positive outcomes in clinical practice for acute ischemic stroke, cryptogenic stroke, unruptured incidental cerebral aneurysms and brain hemorrhage. Viz.ai formed new partnerships with leading healthcare technology organizations to further scale its impact. At the Radiological Society of North America (RSNA) meeting, Viz.ai announced a collaboration with Microsoft to deliver a comprehensive platform of more than 48 diagnostic imaging AI models seamlessly embedded into clinical workflows. Together, Viz.ai and Microsoft aim to help radiologists create more accurate reports more efficiently, streamline communication to treating physicians, and support care team collaboration for appropriate follow-up and treatment for patients. Viz.ai announced a partnership with Cleerly at the American College of Cardiology meeting (ACC) and a partnership with Addario Lung Cancer Medical Institute at the American Society of Clinical Oncology meeting to advance care across cardiology, oncology and neurology. This past year, Viz.ai was recognized by Fast Company’s 50 Most Innovative Companies list , received the Prix Galien Award for Best Digital Health Solution in Pharma, and earned its second Edison Award for Viz Pulmonary Embolism. Viz.ai CEO Dr Chris Mansi was also featured as one of the 100 most influential people in AI by TIME Magazine . Collectively, these honors reflect the company’s innovation and impact on expanding patient access to life-saving treatments. About Viz.ai Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Researchers from Asan Medical Center, South Korea's largest hospital, have developed an AI-based system for analysing coronary artery images prior to coronary angioplasty. Coronary angioplasty is a standard treatment to widen narrowed or blocked coronary arteries indicated in coronary artery diseases such as angina and heart attack. FINDINGS The Asan research team's AI system supports cardiovascular angiography, which is done before a coronary angioplasty by an experienced cardiologist to check on a narrowed artery and determine the appropriate stent. Once an angiogram is uploaded to the system during a procedure, the AI evaluates the internal diameter, lesion length, and degree of stenosis of the artery and then calculates the optimal size of the stent. In a study, which findings have been published in Cardiovascular Interventions under the Journal of the American College of Cardiology, the researchers compared the outcomes of nearly 400 patients in 13 medical institutions whose treatments were supported with AI and those who underwent 3D-based imaging-guided coronary angioplasty. They found that the AI system achieved comparable safety outcomes as the latter considering the minimum stent area – a key success indicator for the heart procedure. The research team also noted the lack of major clinical events, such as death, myocardial infarction, and thrombosis with AI-guided coronary angiography. WHY IT MATTERS Currently, the best and most accurate method to identify coronary artery lesions and support coronary angioplasty is 3D-based high-resolution imaging called intravascular optical coherence tomography. Despite providing an accurate evaluation of artery lesions, the procedure is costly and takes a long time, making it less preferred to use, according to the Asan researchers. The research team proposed an AI-guided system and proved its comparable safety in what could be the world's first study. "Using AI, coronary angiography images can be analysed quickly and objectively without additional time or labour, making coronary intervention possible without error," Jung-min Ahn, AMC professor and study lead, claimed in a statement. He shared that they plan to expand the application of their AI system to cover complex coronary artery lesions, such as left main spleen lesions and graft vascular lesions. MARKET SNAPSHOT While the AMC researchers' AI-based system might be the first to prove its safety, it was not the first to integrate AI in cardiac angiography. United States-based Cleerly and Caristo Diagnostics from the United Kingdom have developed AI to evaluate CT angiograms for heart disease diagnosis. In Australia, publicly-listed company Artrya offers Salix, which also uses AI to detect and assess atherosclerotic plaque in heart CT scans. The product has been approved for sale in Europe and the United Kingdom.